China Isotope & Radiation Corporation (1763) released an announcement indicating anticipated declines in revenue and profit for the year ended 31 December 2025. According to preliminary unaudited management accounts, revenue is expected to fall between RMB6.98 billion and RMB7.21 billion, reflecting a year-on-year decrease of 5% to 8%. Net profit is projected at approximately RMB611.00 million to RMB655.00 million, signifying a decrease of 25% to 30% compared with 2024 results.

Profit attributable to equity shareholders is estimated at about RMB302.00 million to RMB322.00 million, registering a year-on-year drop of roughly 20% to 25%. The decline in overall revenue is primarily linked to reduced performance in the nuclear medical equipment segment. The dip in profit is mainly attributed to supplementary tax payments and late fees at a subsidiary.

The data is based on unaudited figures and may differ from final audited results, which are scheduled for release by the end of March 2026. Shareholders and potential investors are advised to remain cautious when dealing in the company’s securities.